Urinary PCA3 score predicts prostate cancer multifocality

Journal of Urology

Volumn 185, Issue 4, 2011, Pages 1234-1239

  Vlaeminck Guillem, Virginie ^a,b,c   Devonec, Marian ^a,b   Colombel, Marc ^a,b   Rodriguez Lafrasse, Claire ^a,b   Decaussin Petrucci, Myriam ^a,b,c   Ruffion, Alain ^a,b,c  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c Univ Lyon 1   (France)

Author keywords

prostate; prostate cancer antigen 3, human; prostatectomy; prostatic neoplasms; tumor markers, biological

Indexed keywords

PROSTATE CANCER ANTIGEN 3; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CORRELATION ANALYSIS; DIGITAL RECTAL EXAMINATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR LOCALIZATION; TUMOR VOLUME;

ANTIGENS, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; ORGAN SIZE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS;

EID: 79952705614     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.11.072     Document Type: Article

References (29)

1. Bussemakers MJ, van Bokhoven A, Verhaegh GW et al: DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975.
2. de Kok JB, Verhaegh GW, Roelofs RW et al: DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695.
3. Hessels D, Klein Gunnewiek JM, van Oort I et al: DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8.
4. Vlaeminck-Guillem V, Ruffion A, Andre J et al: Urinary prostate cancer 3 test: toward the age of reason? Urology 2010; 75: 447.
5. Groskopf J, Aubin SM, Deras IL et al: APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089.
6. van Gils MP, Hessels D, van Hooij O et al: The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007; 13: 939.
7. Marks LS, Fradet Y, Deras IL et al: PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532.
8. Deras IL, Aubin SM, Blase A et al: PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587.
9. Haese A, de la Taille A, van Poppel H et al: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081.
10. Kirby RS, Fitzpatrick JM and Irani J: Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU Int 2009; 103: 441.
11. Marks LS and Bostwick DG: Prostate cancer specificity of PCA3 gene testing: examples from clinical practice. Rev Urol 2008; 10: 175.
12. Nakanishi H, Groskopf J, Fritsche HA et al: PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179: 1804.
13. Whitman EJ, Groskopf J, Ali A et al: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008; 180: 1975.
14. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA et al: Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008; 68: 1215.
15. Hessels D, van Gils MP, van Hooij O et al: Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010; 70: 10.
16. Chen ME, Johnston D, Reyes AO et al: A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 2003; 27: 1291.
17. Epstein JI, Chan DW, Sokoll LJ et al: Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 160: 2407.
18. Gallina A, Chun FK, Suardi N et al: Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 2008; 101: 1513.
19. Bialkowska-Hobrzanska H, Driman DK, Fletcher R et al: Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue Can J Urol 2006; 13: 2967.
20. Floriano-Sanchez E, Cardenas-Rodriguez N, Castro-Marin M et al: DD3(PCA3) gene expression in cancer and prostatic hyperplasia. Clin Invest Med 2009; 32: E258.
21. Liu AJ, Furusato B, Ravindranath L et al: Quantitative analysis of a panel of gene expression in prostate cancer - with emphasis on NPY expression analysis. J Zhejiang Univ Sci B 2007; 8: 853.
22. Popa I, Fradet Y, Beaudry G et al: Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol 2007; 20: 1121.
23. Balcerczak E, Mirowski M, Sasor A et al: Expression of p65, DD3 and c-erbB2 genes in prostate cancer. Neoplasma 2003; 50: 97.
24. Mouraviev V, Mayes JM and Polascik TJ: Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol 2009; 6: 205.
25. Scales CD Jr, Presti JC Jr, Kane CJ et al: Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy - results from the SEARCH database. J Urol 2007; 178: 1249.
26. Tareen B, Godoy G, Sankin A et al: Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer? BJU Int 2009; 104: 195.
27. Tsivian M, Kimura M, Sun L et al: Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int 2010; 105: 1089.
28. Falzarano SM, Zhou M, Hernandez AV et al: Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy. Urology 2010; 76: 682.
29. Grossklaus DJ, Coffey CS, Shappell SB et al: Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU Int 2001; 88: 722.